Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 June;53(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 June;53(3):311-16

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS  TREATMENT OF HCC AND LIVER METASTASES BY MEANS OF RADIONUCLIDE THERAPY 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 June;53(3):311-16

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Yttrium-90 radioembolization using Thera- Sphere® in the management of primary and secondary liver tumors

Riaz A. 1, Lewandowski R. J. 1, Kulik L. 2, Salem R. 1

1 Department of Radiology Section of Interventional Radiology Robert H Lurie Comprehensive Cancer Center Northwestern University, Chicago, IL, USA 2 Department of Medicine Division of Hepatology Robert H Lurie Comprehensive Cancer Center Northwestern University, Chicago, IL, USA


PDF


Locoregional therapies, such as transarterial chemoembolization, radioembolization and thermal ablation (e.g., radiofrequency ablation) are establishing their roles in the management of liver malignancies. With yYttrium-90 radioembolization therapy (90Y) radionuclide labeled microspheres are injected into the tumor feeding artery. This allows the delivery of a high radioactive dose to the tumor with minimal toxicity to normal tissues. 90Y has demonstrated to be safe and effective in the management of liver tumors. Authors present a review of the literature available for the use of TheraSphere® for radioembolization in the management of liver tumors.

top of page